EBMT 2020 | Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors
Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, outlines the use of JAK1 and JAK2 inhibitors in patients undergoing allogeneic stem-cell transplantation (allo-HSCT) for BCR-ABL negative myeloproliferative neoplasms (MPNs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
